HC Wainwright Has Optimistic Opinion of DWTX FY2026 Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Analysts at HC Wainwright lifted their FY2026 earnings per share estimates for Dogwood Therapeutics in a research note issued on Friday, November 6th. HC Wainwright analyst S. Lee now expects that the company will post earnings per share of ($0.78) for the year, up from their prior estimate of ($0.80). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ Q3 2027 earnings at ($0.16) EPS, Q4 2027 earnings at ($0.16) EPS, FY2027 earnings at ($0.64) EPS, FY2028 earnings at ($0.57) EPS, FY2029 earnings at $0.55 EPS and FY2030 earnings at $1.32 EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Thursday, October 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Stock Down 6.3%

DWTX opened at $1.20 on Tuesday. Dogwood Therapeutics has a fifty-two week low of $0.90 and a fifty-two week high of $7.04. The business has a 50-day moving average of $1.51 and a 200-day moving average of $1.94.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its earnings results on Thursday, November 5th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. The firm had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.10 million.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with viral activation. The company’s programs are designed to address conditions for which persistent or reactivated viral activity may contribute to symptoms and disease progression.

Its lead investigational product, IMC-1, is an oral combination of the antiviral drug famciclovir and the anti-inflammatory drug celecoxib. The company has evaluated IMC-1 in fibromyalgia and has also investigated its potential use in other conditions, including symptoms associated with long COVID.